KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Endovascular Therapy for Post-Thrombotic Syndrome - A Randomized Trial.

Suresh Vedantham, Susan R Kahn, William A Marston, Ido Weinberg, Akhilesh K Sista, Elizabeth A Magnuson, David J Cohen, Suman M Wasan, Mahmood K Razavi, Samuel Z Goldhaber, Kristen M Sanfilippo, Anthony J Comerota, Ezana M Azene, Cassius Iyad Ochoa Chaar, Daniel A Leung, K Pallav Kolli, Sanjeeva P Kalva, Nassir Rostambeigi, Ajinkya Desai, Kush R Desai, Alfonso J Tafur, Bhavraj Khalsa, Elaine Majerus, Borong Wang, Yang Wang, Patricia Nieters, Mary Clare Derfler, Angela Oliver, Cassandra Hardy, Riyaz Bashir, Ronald Winokur, Natalie Weger, Minhaj S Khaja, Aditya Sharma, Naganathan Mani, Pavan Kavali, Siddhant Thukral, Leslie L Lake, Kathryn Mikkelsen, Sameer Parpia, C-TRACT Trial Investigators

N Engl J Med 394(23) 2293-2304

PMID41972998
PMCIDPMC13078690
DOI10.1056/NEJMoa2519001
发表日期2026-04-13
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1 –:CONSORT/入组流程图;Figure 2 -:非 KM 图。
摘要

摘要

BACKGROUND: Post-thrombotic syndrome is common after deep-vein thrombosis and can cause severe symptoms involving the limbs that impair patients' activity and quality of life. Endovascular therapy can eliminate chronic venous obstruction and is hypothesized to reduce the severity of post-thrombotic syndrome. METHODS: We randomly assigned 225 patients with moderate or severe post-thrombotic syndrome and imaging-confirmed iliac-vein obstruction to receive endovascular therapy (iliac-vein stent placement and enhanced antithrombotic therapy) plus standard post-thrombotic syndrome care or standard post-thrombotic syndrome care alone. The severity of post-thrombotic syndrome at 6 months (the primary outcome) was assessed with the validated Venous Clinical Severity Score (VCSS) tool (scores range from 0 to 30, with higher scores indicating more severe post-thrombotic syndrome) by evaluators who were unaware of the group assignments. Key secondary outcomes included venous disease-specific and overall quality of life. RESULTS: At 6 months, the severity of post-thrombotic syndrome was lower in the endovascular-therapy group than in the no-endovascular-therapy group (mean [±SD] VCSS, 8.1±5.1 vs. 10.0±4.9; adjusted difference, -2.0; P = 0.001). Venous disease-specific quality of life as assessed with the Venous Insufficiency Epidemiological and Economic Study Quality of Life questionnaire was better in the endovascular-therapy group than in the no-endovascular-therapy group at 6 months (adjusted difference, 14.5 points; P<0.001), as was overall quality of life as assessed with the Medical Outcomes Study 36-Item Short-Form Health Status Survey physical component summary score (adjusted difference, 6.1 points; P<0.001); scores on both tools range from 0 to 100. Through 6 months, bleeding was more common in the endovascular-therapy group than in the no-endovascular-therapy group (in 11.6% vs. 3.6% of the patients; P = 0.03). CONCLUSIONS: Among patients with moderate or severe post-thrombotic syndrome and iliac-vein obstruction, endovascular therapy led to less severe post-thrombotic syndrome and better health-related quality of life than standard care over a 6-month period but with a higher risk of bleeding. (Funded by the National Heart, Lung, and Blood Institute and others; C-TRACT ClinicalTrials.gov number, NCT03250247.).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1 –CONSORT Diagram The diagram demonstrates the flow of C-TRACT participant randomization, adherence, and follow-up through 6 months by treatment group. The number of patients who met each inclusion and exclusion criterion are delineated in the Supplemental Appendix . EVT denotes endovascular therapy.
非 KM Figure
Figure 2 -Categorical Distribution of VCSS and Villalta Scores The left panel demonstrates the distribution of C-TRACT patients by treatment group at baseline and 6 months follow-up across the 3 established post-thrombotic syndrome (PTS) severity categories on the Venous Clinical Severity Score (VCSS): no/minimal disease (0–3), mild/moderate disease (4–7), and severe disease (>8) ( 14 ). The right panel demonstrates the distribution of patients by treatment group at baseline and 6 months follow-up across the 4 established severity categories on the Villalta PTS Scale: no PTS (0–4), mild PTS (5–9), moderate PTS (10–14), and severe PTS (>15) ( 12 , 16 ). Patients entered the study with moderateor-severe PTS but over 6 months follow-up, many patients shifted to less severe categories, especially in the endovascular therapy (EVT) group.
非 KM Figure